Letbo

Taipei, Taiwan Founded: 2019 • Age: 7 yrs
Automated nucleic acid detection systems and reagents are developed.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products 2 Services tracked
Competitors - Brand Intelligence

About Letbo

Letbo is a company based in Taipei (Taiwan) founded in 2019. Letbo offers products and services including Automated Nucleic Acid Detection System and Nucleic Acid Extraction Reagents.

  • Headquarter Taipei, Taiwan
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Legal Name Labturbo Biotech Corporation
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
    $72.97 M
    -61.2
    as on Dec 31, 2024
  • Net Profit
    $12.96 M
    0
    as on Dec 31, 2024
  • EBITDA
    -$132.12 M
    2.56
    as on Dec 31, 2024
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Letbo

Letbo is a publicly listed company on the TPEX with ticker symbol 7725 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: TPEX · Ticker: 7725 · Sector: Health technology · Taiwan

Products & Services of Letbo

Letbo offers a comprehensive portfolio of products and services, including Automated Nucleic Acid Detection System and Nucleic Acid Extraction Reagents.

Primary

Automated systems are utilized for efficient detection of pathogens and genetic markers, reducing errors in clinical diagnostics and research applications

Reagents are employed for high-purity extraction of RNA and DNA from various samples, ensuring integrity for downstream analyses in diagnostics and studies

Funding Insights of Letbo

Investments & Acquisitions by Letbo

Investments

Financial Statements - Letbo

Letbo Comparisons

+
Add Comparison
Available on Premium

Competitors of Letbo

Latest news on Letbo

Frequently Asked Questions about Letbo

Letbo was founded in 2019.

Letbo is headquartered in Taipei, Taiwan.

Chi Sheng Tai is the current CEO of Letbo.

Letbo was founded in 2019 in Taipei, Taiwan, within the biotechnology sector. Automated systems for nucleic acid detection are provided to support pathogen and genetic marker identification in clinical diagnostics and research settings. Efficiency and accuracy are improved while human error is minimized, yielding consistent outcomes. Reagents for high-purity RNA and DNA extraction from diverse samples are supplied, alongside high-sensitivity options for targeted pathogen and gene testing.

Letbo offers Automated Nucleic Acid Detection System and Nucleic Acid Extraction Reagents.

Yes, Letbo is publicly traded on TPEX under the ticker symbol 7725.

The ticker symbol of Letbo is 7725 on TPEX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available